Shorter Radiation With Focused Boost for HPV-Linked Throat Cancer
Tests a shorter radiation course with a focused boost in adults with HPV-linked throat cancer.
Plain-language title generated from the registry record
Registry title: Stereotactic Boost and Short-course Radiation Therapy for Oropharynx Cancer
Key facts
- Where
- London and Montreal, CanadaSee the 2 sites
- Phase
- Phase 3
Where in Canada
- London Health Sciences CenterLondon, CanadaTaking people
- Centre Hospitalier de l'Université de MontréalMontreal, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre hospitalier de l'Université de Montréal (CHUM)
- Trial code
- NCT04178174
- Record updated
- 24 August 2026
- Original description
This is a randomized clinical trial comparing the outcomes of short-course chemoradiation consisting in stereotactic boost to the gross tumor and de-esclalated chemoradiation to the elective neck in human papilloma associated oropharynx cancer vs. the current standard 7-week course chemoradiation.Read full original descriptionShow less
Stereotactic Boost and SHOrt-course Radiation Therapy for HPV-associated OroPharynx Cancer Trial: A Randomized Multicentric Phase III Trial
This is a randomized clinical trial comparing the outcomes of short-course chemoradiation consisting in stereotactic boost to the gross tumor and de-esclalated chemoradiation to the elective neck in human papilloma associated oropharynx cancer vs. the current standard 7-week course chemoradiation.
Inclusion: Age ≥18 years; Ability to provide written informed consent; Eastern Cooperative Oncology Group (ECOG) performance status 0-2; Biopsy proven diagnosis of squamous cell carcinoma of the oropharynx; Positive for HPV by p16 immunohistochemistry (IHC) or HPV in-situ hybridization (ISH); Clinical stage T1-3, N1 M0 (Stage I-II) as per AJCC 8th edition; Primary tumor < 30 cc; Planned for curative chemoradiation; For females of child-bearing age, a negative pregnancy test.
Exclusion: Previous irradiation of the head and neck region; Previous surgery of the HNC region (except for incisional or excisional biopsies); Non-Cisplatin concurrent chemotherapy; Prior induction chemotherapy; Connective tissue disease; Any medical condition that could, in the opinion of the investigator, prevent follow-up after radiotherapy; Clinical N3 classification, as per AJCC 8th edition; Clinically overt extranodal extension (ENE). As per AJCC 8th edition, clinically overt ENE is defined as invasion of the skin, infiltration of musculature/fixation to adjacent structures on clinical examination, cranial nerve, brachial plexus, sympathetic trunk or phrenic nerve invasion with dysfunction); Pregnancy or breastfeeding.